Summary Cancer incidence among 3,727 offspring of women hospitalised for epilepsy in Denmark between 1933 and 1962 was evaluated in a record-linkage survey with the national cancer registry. The children were identified from hospital charts, population listings, and parish registries. For all children (born before and after their mothers' hospitalisation), no excess of cancer was found in comparison with the general population (49 observed vs 53.8 expected). Among the 2,579 children born after their mothers' first admission for epilepsy, and thus presumably exposed in utero to anticonvulsant drugs, 14 cancers were identified compared to 13.8 expected (relative risk 1.0; 95% confidence interval 0.6-1.7). Contrary to some previous reports, cancers of the brain and nervous system were not significantly increased (3 observed vs 2.2 expected). These data provide no evidence that anticonvulsant drugs are transplacental carcinogens, and indicate that overall increases in risk as high as 80% are unlikely.
The relation of childhood neoplasms to maternal epilepsy and use of anticonvulsants has been suggested in several studies. In a large case-control study of childhood cancer, prenatal exposure to anticonvulsant drugs was implicated (Sanders & Draper, 1979) , but subsequent analyses suggested a closer relationship to maternal epilepsy rather than to its treatment (Gilman et al., 1989) . A case-control study of childhood brain cancer revealed an association with barbiturate exposure in utero and in early life (Gold et al., 1978 (Gold et al., , 1979 , although this finding was not confirmed in two cohort studies (Annegers et al., 1979; Heinonen et al., 1977) or in a recent case-control study (Goldhaber et al., 1990) . Case reports have related neuroblastoma to the fetal hydantoin syndrome, a constellation of birth defects among offspring of mothers receiving diphenylhydantoin (phenytoin), but it is not clear if the association is etiologic or a chance event (Koren et al., 1989) . Excess brain tumours have occurred in cohort studies of epileptics treated with anticonvulsant drugs (Clemmesen et al., 1974; White et al., 1979; Shirts et al., 1986; Olsen et al., 1989) , but the finding is complicated by the fact that seizures may be an early manifestation of the brain tumour. Further, some studies have suggested relationships of lung cancer following phenobarbital use (Friedman, 1981; Olsen et al., 1989) , and lymphomas after phenytoin (Li et al., 1975) . In a large follow-up study of cancer among 8,004 epileptic patients exposed to anticonvulsive drugs in Denmark, we found little evidence that phenobarbitone or hydantoins are carcinogenic to humans, although small risks of lung cancer and non-Hodgkin's lymphoma could not be ruled out (Olsen et al., 1989) .
To clarify the potential of anticonvulsant drugs to be transplacental carcinogens, we identified the offspring of 3,758 women hospitalised for epilepsy between 1933 and 1962.
Methods

Study population
The study population included the children of 3,758 female patients admitted for epilepsy to the Filadelfia treatment community in Denmark between 1933 and 1962 . Details concerning the identification and selection of the patients have been given in earlier publications (Clemmesen & Hjalgrim-Jensen, 1978; Olsen et al., 1989) . Table I (Ewertz & Jensen, 1984) . Among those with children, the family size was fairly similar to the national average (Ewertz & Duffy, 1988) .
Cancer incidence and analysis A complete description and evaluation of the Danish Cancer Registry have been given earlier (Jensen et al., 1985) . Records on the offspring of female epileptics were linked with the files of the Cancer Registry following a previously established procedure (Jensen, 1980 (Rothman & Boice, 1979) .
Results
The survey on drug use among a sample (n = 130) of female epileptic patients indicated that 76% had been treated with phenobarbitone, 59% with hydantoins, and 30% with primidone. Table III gives the proportion of female epileptics who ever used one or more of the specified groups of drug during four consecutive calendar periods, and the typical daily doses prescribed. For 13% of the women in the sample, evidence of anticonvulsant therapy was not apparent from their hospital records.
Among the 3,727 offspring included in the study (1,933 boys and 1,794 girls), 3,395 (91%) were known to be alive at the end of the study period (31 December 1986), 243 (7%) had died, and 89 (2%) had emigrated. In the total group of children, 1,148 were born before the initial admittance of the mother to Filadelfia, and 2,579 after hospitalisation. A total of 42,154 person-years of follow-up were accumulated in the former group and 57,741 in the latter, for an average followup of 37.5 years (maximum, 65) and 22.4 years (maximum, 50), respectively.
Overall, 49 cancers were identified compared to 53.8 expected (RR 0.91; 95% CI 0.7-1.2). Among the group of offspring born before the mothers' initial admission to Filadelfia, 35 developed a cancer compared to 40.0 expected (RR 0.88; 95% CI 0.6-1.2). No significant increase in risk for any cancer was found, although small excesses were noted for lung cancer (7 versus 3.2) and nonmelanoma skin cancer (7 versus 3.8). As shown in Table IV , 14 cancers occurred among offspring born after the mothers' initial admission compared to 13.8 expected (RR 1.0; 95% CI 0.6-1.7). No excess risk was observed for any specific cancer. Table V shows the tumour types, sex, age at diagnosis, and maternal drug histories of children (born after their mothers' initial admission) who developed cancer. Two of the three brain cancer cases were astrocytomas; however, no anticonvulsants were given during pregnancy for one case, and in the other no information on therapy was available. One of the two children with leukaemia also had Down's syndrome.
Discussion
Since 1971 when prenatal exposure to synthetic estrogens was linked to clear cell adenocarcinomas of the vagina and cervix (Herbst et al., 1971) , there has been great interest in whether other drugs pose transplacental hazards. Some suspicion has centered on phenytoin, because of clinical reports of neuroblastoma with the fetal hydantoin syndrome. The relation of prenatal barbiturate exposure to childhood brain tumours was raised by one study (Gold et al., 1978 (Gold et al., , 1979 , although not confirmed by others (Annegers et al., 1979; Heinonen et al. , 1977; Goldhaber et al., 1990) . Further interest has been aroused by reports that after postnatal exposure hydantoins may be related to lymphoma (Li et al., 1975) , and phenobarbitone to lung cancer (Friedman, 1981) .
In this cohort study of 3,727 children born to epileptic mothers, we found no evidence of increased cancer risk. A maternal history of hospitalisation for epilepsy was used as a proxy for fetal drug exposure, and cancer was evaluated in offspring born both before and after hospitalisation. No forms of cancer could be linked to either a maternal history of epilepsy or exposure in utero to anticonvulsant drugs. However, despite the relatively large number of exposed offspring in our study, the number of observed cancers was relatively small, and the power to detect the relatively small relative risks suggested in several previous studies was low. While two-fold risks for all cancer sites combined can be reasonably excluded in our series, lower level risks cannot. For specific cancer sites, the upper confidence limits indicate that three-fold and greater risks would not be incompatible with the current observations. In addition, we could not obtain complete drug histories on all individuals, only details from a sample and from those mothers whose children developed malignancy. Also, about 13% of the women who were hospitalised for epilepsy apparently received little or no anticonvulsant treatment, so that fetal exposures are less certain. On the other hand, we had relatively complete identification of children born to epileptic mothers and relatively complete ascertainment of cancer incidence through linkage with available national record systems. The period of observation was long, and cancers through early adulthood (ages 24 through 53 years) could be identified for the majority of offspring.
Prenatal exposures to anticonvulsants were likely to be heaviest among the 2,579 children born after hospitalisation of their mothers for epilepsy. This subgroup showed no excess risk of any form of cancer. Although the developing fetus may be especially sensitive to the effects of carcinogenic exposures, these data suggest that if anticonvulsants are carcinogenic, our study size was too small to detect small increases in risk, the cumulative dose at critical periods was too low, or the observational period was too short to accommodate the latency for certain forms of cancer. aChild also had Down's syndrome.
